Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal 2009, 135: 1588-1595. PMID: 19188545, DOI: 10.1378/chest.08-1430.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPneumonectomyPreoperative CareProbabilityRespiratory Function TestsRisk AssessmentSurvival AnalysisConceptsNon-small cell lung cancerCell lung cancerSurgical resectionLung cancerPulmonary toxicityResectable early stage non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized phase 2 trialPulmonary function test resultsSecondary end pointsCombination of gemcitabinePhase 2 trialPulmonary function testsGemcitabine-based chemotherapyFunction test resultsTotal lung capacityEligible patientsNonplatinum regimensDyspnea scoreInterstitial pneumonitisPreoperative chemotherapyFunction testsSmoking statusClinical symptomsPreoperative setting